Patient groups | Treatment | Treatment year | Total | ||
---|---|---|---|---|---|
1st year | 2nd year | 3rd year | |||
Base analysis | |||||
 All patients | Dapagliflozin | 832,312 | 847,560 | 862,349 | 2,542,221 |
DPP-4i | 844,608 | 870,883 | 884,517 | 2,600,008 | |
Difference | 12,296 | 23,323 | 22,169 | 57,787 | |
 Patients with underlying CVD | Dapagliflozin | 1,334,443 | 1,376,727 | 1,417,845 | 4,129,014 |
DPP-4i | 1,373,319 | 1,448,896 | 1,484,380 | 4,306,594 | |
Difference | 38,876 | 72,169 | 66,535 | 177,580 | |
 Patients without underlying CVD | Dapagliflozin | 755,451 | 764,393 | 772,895 | 2,292,739 |
DPP-4i | 760,709 | 774,577 | 782,840 | 2,318,126 | |
Difference | 5258 | 10,184 | 9945 | 25,387 | |
Sensitivity analysis | |||||
 All patients | Dapagliflozin | 838,482 | 859,691 | 880,237 | 2,578,409 |
DPP-4i | 848,827 | 879,127 | 898,553 | 2,626,506 | |
Difference | 10,345 | 19,436 | 18,317 | 48,097 | |
 Patients with underlying CVD | Dapagliflozin | 1,347,676 | 1,402,655 | 1,455,945 | 4,206,275 |
DPP-4i | 1,379,600 | 1,460,981 | 1,508,597 | 4,349,179 | |
Difference | 31,925 | 58,327 | 52,653 | 142,904 | |
 Patients without underlying CVD | Dapagliflozin | 759,669 | 772,623 | 784,938 | 2,317,229 |
DPP-4i | 764,829 | 782,650 | 794,789 | 2,342,268 | |
Difference | 5160 | 10,027 | 9851 | 25,039 |